Biotech rating scheme
Claravant aiming to rate biotech programs on confidential info
Claravant Analytics LLC is aiming to change the biotech investment ecosystem by leveling the playing field for public investors that don't have access to confidential information. The firm plans to serve as a third-party intermediary that signs non-disclosure agreements with companies to gain access to confidential information, which it then will analyze to rate therapeutic programs.
The company debuted in April and already is evaluating programs for multiple clients, according to CEO Chris Plaford.
Claravant will look across the board in terms of disease space and stage of development. The firm also will evaluate diagnostics, though Plaford expects the majority of the initial investor demand will be for therapeutics, where he said clinical and regulatory issues are more likely to cause significant delays or failures.
The incentive for biotechs to sign up is a comprehensive report from Claravant's team, which Plaford said can help companies and their boards identify program problems earlier in development and potentially prevent delays down the line.
Companies will pay Claravant a fee depending on